Hvsen Biotech: Subsidiary "Yinqiao Lanjin Oral Solution" Obtains New Veterinary Drug Registration Certificate

Zhitong
2025.09.30 07:55

In 2025, Hubei Hvsen Biotech Co., Ltd., a subsidiary of Wuhan Hvsen Biotech Co., Ltd., jointly applied with other units for the "Yinqiao Lantian Oral Solution," which received the "New Veterinary Drug Registration Certificate" issued by the Ministry of Agriculture and Rural Affairs. This veterinary drug is classified as a Class III new veterinary drug, with a monitoring period of 3 years, and is indicated for treating colds caused by external wind-heat in chickens. Currently, there is a high incidence of respiratory diseases in poultry, and there are limited compliant green and antibiotic-free drugs available; this drug can effectively prevent and treat chicken respiratory diseases. Before the product is launched, it must obtain the veterinary drug product approval number. The successful development of the new veterinary drug reflects the company's investment in innovation, enriches the category of traditional Chinese medicine, meets industry development requirements, and is beneficial for enhancing competitiveness, but it will not have a significant impact on performance in the short term. The company reminds investors to pay attention to risks

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.